| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 42, 210-217, Copyright © 1996 by American Association for Clinical Chemistry
W Withold, U Schulte and H Reinauer
Institut fur Klinische Chemie und Laboratoriumsdiagnostik, Heinrich- Heine-Universitat Dusseldorf, Germany.
We report the performance characteristics of an assay for determination of bone alkaline phosphatase (ALP) activity after immunoadsorption in microplate wells. Between-run imprecision was between 7.1% and 11.2%. The detection limit was 1.0 U/L. Comparisons with an immunoradiometric test for determination of bone ALP mass concentrations yielded the following regression equation: y = 3.11 + 1.33x with y, the bone ALP activity concentration (U/L) (and x, the bone ALP mass concentration microgram/L) (r +=0.974, n = 103). Using sera from patients with liver diseases and sera from patients with secondary hyperparathyroidism yielded a cross-reactivity of 20% for circulating liver ALP (and its membrane-bound isoform). In patients receiving renal transplants, Z- score analysis revealed that after transplantation the increase in bone ALP activity is more pronounced than total ALP activity. In tumor patients, receiver-operating characteristic analysis revealed that bone ALP activity shows the same diagnostic efficacy as total ALP activity in the detection of bone metastases (as assessed by bone scintigraphy). In multiple myeloma patients, suppressed osteoblast activity was well detectable by bone ALP activity determination.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. W. Woitge, E. Horn, A. V. Keck, B. Auler, M. J. Seibel, and M. Pecherstorfer Biochemical Markers of Bone Formation in Patients with Plasma Cell Dyscrasias and Benign Osteoporosis Clin. Chem., April 1, 2001; 47(4): 686 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Broyles, R. G. Nielsen, E. M. Bussett, W. D. Lu, I. A. Mizrahi, P. A. Nunnelly, T. A. Ngo, J. Noell, R. H. Christenson, and B. C. Kress Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase Clin. Chem., October 1, 1998; 44(10): 2139 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Price, T. P. Milligan, and C. Darte Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum Clin. Chem., November 1, 1997; 43(11): 2052 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Withold, H. W. Woitge, and M. J. Seibel More on Total and Bone-Specific Alkaline Phosphatase • Authors of the article referred to respond: Clin. Chem., September 1, 1997; 43(9): 1670 - 1671. [Full Text]
|
|
|
|
|
|
W. Withold, F. P. Armbruster, M. Karmatschek, and H. Reinauer Bone sialoprotein in serum of patients with malignant bone diseases Clin. Chem., January 1, 1997; 43(1): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H.-J. Hsu and K.-S. Tsai Different Age-Related Trends of Bone and Nonbone Forms of Alkaline Phosphatase in Chinese Men and Women Clin. Chem., January 1, 1997; 43(1): 186 - 188. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
